Patents by Inventor Manli WANG

Manli WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230293485
    Abstract: The present invention relates to an application of an artemisinin compound in treatment of coronavirus infection. Specifically, the present invention provides an application of the compound, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of medicines. The medicines are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2), and the compound is selected from one or more of artemisinin, arteether, artemether, artemisia ketone, dihydroartemisinin, artesunate, arteannuin B, and artemisinic acid.
    Type: Application
    Filed: July 22, 2021
    Publication date: September 21, 2023
    Inventors: Ruiyuan Cao, Manli Wang, Wei Li, Lei Zhao, Jingjing Yang, Yuexiang Li, Shiyong Fan, Xinbo Zhou, Dian Xiao, Zhihong Hu, Song Li, Wu Zhong
  • Publication number: 20230263811
    Abstract: The present application relates to use of cannabidiol in the preparation of a drug for treating coronavirus infections. The present invention specifically relates to cannabidiol, or a geometric isomer, pharmaceutically acceptable salt, solvate or hydrate thereof, or use of a pharmaceutical composition comprising any one or more of the above components in the preparation of a drug for preventing and/or treating diseases or infections caused by a coronavirus.
    Type: Application
    Filed: July 19, 2021
    Publication date: August 24, 2023
    Inventors: Wu Zhong, Yong Qin, Manli Wang, Ruiyuan Cao, Shiyong Fan, Zhihong Hu, Song Li
  • Publication number: 20230263748
    Abstract: The present invention relates to an application of benflumetol and derivatives thereof in treatment of coronavirus infection, and specifically provides uses of a compound represented by formula A, and a stereoisomer, a pharmaceutically acceptable salt, a solvate or a hydrate thereof in preparation of drugs. The drugs are used for treating diseases or infection caused by coronavirus (preferably SARS-CoV-2).
    Type: Application
    Filed: July 22, 2021
    Publication date: August 24, 2023
    Inventors: Ruiyuan CAO, Manli WANG, Wei LI, Lei ZHAO, Jingjing YANG, Yuexiang LI, Shiyong FAN, Xinbo ZHOU, Dian XIAO, Zhihong HU, Song LI, Wu ZHONG
  • Publication number: 20230218606
    Abstract: Disclosed are hydroxychloroquine or chloroquine, or a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound, and the use thereof in the treatment of diseases or infections caused by SARS-CoV-2.
    Type: Application
    Filed: June 2, 2020
    Publication date: July 13, 2023
    Inventors: Wu Zhong, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Ruiyuan Cao, Wei Li, Shiyong Fan, Xinbo Zhou, Song Li
  • Publication number: 20230210807
    Abstract: Disclosed are the use of a benzoate compound as shown in formula I, a geometric isomer thereof, a pharmaceutically acceptable salt thereof and/or a solvate thereof or a hydrate thereof, and a pharmaceutical composition containing the above-mentioned compound in the prevention and treatment of SARS-CoV-2 infections.
    Type: Application
    Filed: July 15, 2020
    Publication date: July 6, 2023
    Inventors: Wu ZHONG, Ruiyuan CAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Wei LI, Yuexiang LI, Lei ZHAO, Shiyong FAN, Song LI
  • Publication number: 20230119764
    Abstract: A compound represented by the general Formula I, a geometric isomer thereof, or a pharmaceutically acceptable salt thereof, and/or a solvate thereof, and/or a hydrate thereof for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or an asymptomatic or symptomatic SARS-CoV-2 infection, and an application of the compound represented by the general Formula I, the geometric isomer thereof, or the pharmaceutically acceptable salt thereof, and/or the solvate thereof, and/or the hydrate thereof in preparation of a product for preventing and/or treating a pulmonary disease or symptom associated with SARS-CoV-2 or asymptomatic or symptomatic SARS-CoV-2 infection,
    Type: Application
    Filed: July 13, 2020
    Publication date: April 20, 2023
    Inventors: Wu Zhong, Chengfeng Qin, Xinbo Zhou, Yongqiang Deng, Jiqiang Hu, Qingping Jin, Bin Yu, Ruiyuan Cao, Manli Wang, Xiaofeng Li, Nana Zhang, Shiyong Fan, Zhihong Hu, Song Li
  • Publication number: 20230077704
    Abstract: Nitazoxanide represented by formula I and an active form thereof, tizoxanide compound, represented by formula II, a geometric isomer thereof and pharmaceutically acceptable salt thereof and/or solvate thereof and/or hydrate thereof, and a pharmaceutical composition containing this compound, used for preventing and/or treating coronavirus (such as SARS-CoV-2) infection.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 16, 2023
    Inventors: Wu Zhong, Gengfu Xiao, Zhihong Hu, Manli Wang, Ruiyan Cao, Leike Zhang, Wei Li, Yuexiang Li, Lei Zhao, Song Li
  • Publication number: 20230071014
    Abstract: A use of ritonavir, or a geometric isomer, pharmaceutically acceptable salt, solvate, and/or hydrate thereof, and a pharmaceutical composition containing the above compound in treating a SARS-CoV-2 infections.
    Type: Application
    Filed: July 15, 2020
    Publication date: March 9, 2023
    Inventors: Wu Zhong, Zhihong Hu, Gengfu Xiao, Ruiyuan Cao, Manli Wang, Leike Zhang, Wei Li, Shiyong Fan, Song Li
  • Publication number: 20220193039
    Abstract: Related is application of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy, particularly related to use of a compound of formula I in the preparation a medicament, wherein the medicament is used to prevent and/or treat a disease associated with a virus.
    Type: Application
    Filed: July 15, 2021
    Publication date: June 23, 2022
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Xinbo ZHOU, Ruiyuan CAO, Dian XIAO, Manli WANG, Shiyong FAN, Zhihong HU, Song LI
  • Patent number: 11318135
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Grant
    Filed: July 16, 2021
    Date of Patent: May 3, 2022
    Assignee: Academy of Military Medical Sciences
    Inventors: Wu Zhong, Ruiyuan Cao, Cheng Cao, Ting Gao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Song Li
  • Publication number: 20220105077
    Abstract: Related is application of 2,4,5-trisubstituted 1,2,4-triazolones in antiviral therapy, particularly related to use of a compound of formula I in the preparation a medicament, wherein the medicament is used to prevent and/or treat a disease associated with a virus.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Xinbo ZHOU, Ruiyuan CAO, Dian XIAO, Manli WANG, Shiyong FAN, Zhihong HU, Song LI
  • Publication number: 20210346411
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Wei LI, Yuexiang LI, Lei ZHAO, Shiyong FAN, Song LI
  • Publication number: 20210346376
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Cheng CAO, Ting GAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Song LI
  • Publication number: 20210220353
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Cheng CAO, Ting GAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Song LI
  • Publication number: 20210220377
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan Cao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Wei Li, Yuexiang Li, Lei Zhao, Shiyong Fan, Song Li